Insulet Co. (NASDAQ:PODD) Shares Purchased by Duality Advisers LP

Duality Advisers LP boosted its stake in shares of Insulet Co. (NASDAQ:PODD) by 15.9% in the fourth quarter, Holdings Channel reports. The fund owned 10,102 shares of the medical instruments supplier’s stock after purchasing an additional 1,387 shares during the period. Duality Advisers LP’s holdings in Insulet were worth $2,192,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Qube Research & Technologies Ltd raised its stake in shares of Insulet by 227.3% during the third quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock worth $61,673,000 after purchasing an additional 268,553 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Insulet by 119.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock valued at $17,223,000 after buying an additional 43,147 shares during the period. Asset Management One Co. Ltd. raised its position in Insulet by 33.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock worth $8,048,000 after buying an additional 9,240 shares during the last quarter. Graham Capital Management L.P. raised its position in Insulet by 689.8% during the 3rd quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock worth $3,683,000 after buying an additional 20,171 shares during the last quarter. Finally, Aquila Investment Management LLC acquired a new stake in shares of Insulet in the 4th quarter worth $1,302,000.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Barclays dropped their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Piper Sandler dropped their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. JPMorgan Chase & Co. increased their target price on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Finally, Stifel Nicolaus lifted their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $243.21.

Insulet Price Performance

Shares of PODD stock traded down $1.70 during mid-day trading on Monday, reaching $164.55. The stock had a trading volume of 135,713 shares, compared to its average volume of 864,688. The company has a market cap of $11.52 billion, a P/E ratio of 56.70, a price-to-earnings-growth ratio of 2.99 and a beta of 0.98. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $335.91. The business has a 50-day simple moving average of $173.97 and a 200 day simple moving average of $179.15.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. During the same period last year, the firm posted $0.55 EPS. The firm’s revenue for the quarter was up 37.9% on a year-over-year basis. On average, sell-side analysts anticipate that Insulet Co. will post 3.08 earnings per share for the current year.

Insider Transactions at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.90% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.